Southampton, UK – July 29: If bacteria had nightmares, their boogeymen would undoubtedly be phages. These viruses are masterfully engineered to locate, infect, and exterminate bacteria – a battle they've been waging for billions of years. This ancient rivalry is now providing insights into tackling antibiotic-resistant infections.
With the rise of bacteria capable of resisting antibiotics, infections that were once manageable are now daunting challenges, and sometimes even untreatable. This global predicament, known as antimicrobial resistance (AMR), claims over a million lives annually, and that figure is climbing rapidly. The World Health Organization has listed AMR among the top ten global public health threats.
Enter phage therapy – the application of phages to combat bacterial infections – which is garnering increasing attention. Phages have a remarkable specificity, making them proficient at targeting even antibiotic-resistant strains. In several compassionate-use instances within the UK, phages have succeeded where all antibiotics had failed. However, phages still encounter a significant obstacle: the bacteria themselves.
Bacteria have developed intricate mechanisms to identify and neutralize phages. These defences are varied: some cleave viral DNA, others block entry, and some instigate an intracellular shutdown to thwart viral dominance. A recent study published in Cell unveils a different system, named Kiwa, which behaves like a sensor within the bacterial membrane, detecting preliminary signs of an attack.
What Kiwa precisely senses remains a mystery, yet evidence hints it responds to mechanical stress when a phage attaches to a cell and injects its DNA. Once activated, Kiwa acts swiftly, halting the phage’s component production, thereby preventing the infection from overtaking the cell.
Phages, however, evolve counter-strategies. In our experiments, we observed two distinct tactics. Some phages acquired minor mutations in the proteins used for bacterial attachment – subtle alterations allowing them to bypass Kiwa’s detection. Others permitted detection but evaded the repercussions.
These phages had mutations in a viral protein, apparently linked to Kiwa's shutdown of the infection. The exact mechanics remain unclear, but the outcome is evident: a few changes enable the virus to continue replicating even after Kiwa's activation.
This evolutionary prowess makes phages potent allies and promising tools for infection management. Yet, it underscores a significant challenge: to harness phage therapy effectively, understanding these microbial confrontations is crucial.
Rules of Engagement: If a bacterial strain employs a defence like Kiwa, certain phages will face insurmountable obstacles. Yet some, with fitting mutations, might prevail. Thus, the right phage choice isn’t mere trial and error but relies on understanding the engagement rules.
Analyzing defence systems like Kiwa deepens our understanding of these rules. It elucidates phage failures and successes and provides insight into designing improved phage therapies. Eventually, we might predict bacterial defence mechanisms a strain harbors and select phages either naturally adept or artificially crafted to bypass them.
This philosophy drives our expanding phage collection initiative. We're amassing phages from the UK and beyond – including public submissions from places like dirty water, often phage goldmines – and testing their efficacy against bacterial defences. With over 600 variants catalogued, this resource aims to steer future phage therapies, ensuring that the right phage combats the right infection.
Kiwa represents just one fragment of this complex puzzle. Bacteria encode numerous defence systems, each contributing layers of complexity – and opportunity – to this microbial arms race. As we learn more, our interventions become more precise.
This isn’t a novel conflict. For billions of years, bacteria and phages have been entangled in this struggle. But now, we’re beginning to eavesdrop. And by mastering their evolved strategies, we might unearth new treatments for infections that antibiotics can no longer combat.
(Only the headline of this report may have been reworked by Editorji; the rest of the content is auto-generated from a syndicated feed.)
